{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:28:29Z","timestamp":1788326909587,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T00:00:00Z","timestamp":1528934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41431-018-0197-0","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T13:31:59Z","timestamp":1528983119000},"page":"1417-1423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD)"],"prefix":"10.1038","volume":"26","author":[{"given":"Erika K. S. M.","family":"Leenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"Westdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Loeffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoline","family":"Hoogerbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn C. J.","family":"Jongmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,14]]},"reference":[{"key":"197_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/jmedgenet-2013-102238","volume":"51","author":"HF Vasen","year":"2014","unstructured":"Vasen HF, Ghorbanoghli Z, Bourdeaut F, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium \u201cCare for CMMR-D\u201d (C4CMMR-D). J Med Genet. 2014;51:283\u201393.","journal-title":"J Med Genet"},{"key":"197_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","volume":"378","author":"J Burn","year":"2011","unstructured":"Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081\u20137.","journal-title":"Lancet"},{"key":"197_CR3","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3899\/jrheum.090153","volume":"37","author":"J Bourre-Tessier","year":"2010","unstructured":"Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416\u201321.","journal-title":"J Rheumatol"},{"key":"197_CR4","first-page":"290","volume":"59","author":"MD Ricciardone","year":"1999","unstructured":"Ricciardone MD, Ozcelik T, Ceher B, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999;59:290\u20133.","journal-title":"Cancer Res"},{"key":"197_CR5","first-page":"294","volume":"59","author":"Q Wang","year":"1999","unstructured":"Wang Q, Lasset C, Desseigne F, Frappaz D, et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 1999;59:294\u20137.","journal-title":"Cancer Res"},{"key":"197_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng.3202","volume":"47","author":"A Shlien","year":"2015","unstructured":"Shlien A, Campbell BB, de Borja R, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47:257\u201362.","journal-title":"Nat Genet"},{"key":"197_CR7","volume-title":"GeneReiews(R)","author":"W Kohlmann","year":"1993","unstructured":"Kohlmann W, Gruber SB. Lynch Syndrome. In: Pagon RA, et al. Eds. GeneReiews(R). Seattle (WA): University of Washington; 1993."},{"key":"197_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra012242","volume":"348","author":"HT Lynch","year":"2003","unstructured":"Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919\u201332.","journal-title":"N Engl J Med"},{"key":"197_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ejca.2010.12.024","volume":"47","author":"P Manders","year":"2011","unstructured":"Manders P, Spruijt L, Kets CM, et al. Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. Eur J Cancer. 2011;47:1407\u201313.","journal-title":"Eur J Cancer"},{"key":"197_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/pbc.24019","volume":"59","author":"CA Durno","year":"2012","unstructured":"Durno CA, Aronson M, Tabori U, Malkin D, Gallinger S, Chan HS. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer. 2012;59:652\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"197_CR11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1053\/j.gastro.2017.02.011","volume":"152","author":"C Durno","year":"2017","unstructured":"Durno C, Boland CR, Cohen S, et al. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2017;152:1605\u201314.","journal-title":"Gastroenterology"},{"key":"197_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ejca.2013.12.005","volume":"50","author":"D Bakry","year":"2014","unstructured":"Bakry D, Aronson M, Durno C, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur J Cancer. 2014;50:987\u201396.","journal-title":"Eur J Cancer"},{"key":"197_CR13","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mds113","volume":"23","author":"C Bosetti","year":"2012","unstructured":"Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403\u201315.","journal-title":"Ann Oncol"},{"key":"197_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","volume":"10","author":"J Cuzick","year":"2009","unstructured":"Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer preention: an international consensus statement. Lancet Oncol. 2009;10:501\u20137.","journal-title":"Lancet Oncol"},{"key":"197_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","volume":"294","author":"NR Cook","year":"2005","unstructured":"Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial. JAMA. 2005;294:47\u201355.","journal-title":"JAMA"},{"key":"197_CR16","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1056\/NEJMoa0801297","volume":"359","author":"J Burn","year":"2008","unstructured":"Burn J, Bishop DT, Mecklin JP, Macrae F, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359:2567\u201378.","journal-title":"N Engl J Med"},{"key":"197_CR17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603\u201313.","journal-title":"Lancet"},{"key":"197_CR18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741\u201350.","journal-title":"Lancet"},{"key":"197_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","volume":"159","author":"NR Cook","year":"2013","unstructured":"Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77\u201385.","journal-title":"Ann Intern Med"},{"key":"197_CR20","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602\u201312.","journal-title":"Lancet"},{"key":"197_CR21","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591\u2013601.","journal-title":"Lancet"},{"key":"197_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/CCO.0000000000000098","volume":"26","author":"RE Langley","year":"2014","unstructured":"Langley RE, Rothwell PM. Aspirin in gastrointestinal oncology: new data on an old friend. Curr Opin Oncol. 2014;26:441\u20137.","journal-title":"Curr Opin Oncol"},{"key":"197_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10689-013-9650-y","volume":"12","author":"J Burn","year":"2013","unstructured":"Burn J, Mathers JC, Bishop DT. Chemopreention in Lynch syndrome. Fam Cancer. 2013;12:707\u201318.","journal-title":"Fam Cancer"},{"key":"197_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bmb\/ldw028","volume":"119","author":"J Burn","year":"2016","unstructured":"Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. Br Med Bull. 2016;119:17\u201324.","journal-title":"Br Med Bull"},{"key":"197_CR25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa067208","volume":"356","author":"AT Chan","year":"2007","unstructured":"Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131\u201342.","journal-title":"N Engl J Med"},{"key":"197_CR26","doi-asserted-by":"publisher","first-page":"233re2","DOI":"10.1126\/scitranslmed.3008481","volume":"6","author":"SP Fink","year":"2014","unstructured":"Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6:233re2.","journal-title":"Sci Transl Med"},{"key":"197_CR27","doi-asserted-by":"publisher","first-page":"17279","DOI":"10.3390\/ijms140917279","volume":"14","author":"S Temraz","year":"2013","unstructured":"Temraz S, Mukherji D, Shamseddine A. Potential targets for colorectal cancer prevention. Int J Mol Sci. 2013;14:17279\u2013303.","journal-title":"Int J Mol Sci"},{"key":"197_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.yexcr.2008.12.010","volume":"315","author":"A Strillacci","year":"2009","unstructured":"Strillacci A, Griffoni C, Sansone P, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res. 2009;315:1439\u201347.","journal-title":"Exp Cell Res"},{"key":"197_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-14-1","volume":"14","author":"HM Roelofs","year":"2014","unstructured":"Roelofs HM, Te Morsche RH, an Heumen BW, Nagengast FM, Peters WH. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol. 2014;14:1.","journal-title":"BMC Gastroenterol"},{"key":"197_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","volume":"68","author":"P Patrignani","year":"2016","unstructured":"Patrignani P, Patrono C. Aspirin and Cancer. J Am Coll Cardiol. 2016;68:967\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"197_CR31","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","volume":"23","author":"JR Brown","year":"2005","unstructured":"Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840\u201355.","journal-title":"J Clin Oncol"},{"key":"197_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2016.07.030","volume":"151","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nishihara R, Qian ZR, Song M, et al. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes. Gastroenterology. 2016;151:879\u201392.e4.","journal-title":"Gastroenterology"},{"key":"197_CR33","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, an der Veen AG, Bottcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell"},{"key":"197_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-642-30331-9_7","volume":"191","author":"PM Rothwell","year":"2013","unstructured":"Rothwell PM. Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. Recent Results Cancer Res. 2013;191:121\u201342.","journal-title":"Recent Results Cancer Res"},{"key":"197_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3757-8","volume":"17","author":"SK Veettil","year":"2017","unstructured":"Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, Chaiyakunapruk N. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer. 2017;17:763.","journal-title":"BMC Cancer"},{"key":"197_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1074-7613(03)00177-8","volume":"19","author":"BD Elzey","year":"2003","unstructured":"Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity. 2003;19:9\u201319.","journal-title":"Immunity"},{"key":"197_CR37","doi-asserted-by":"publisher","first-page":"E2165","DOI":"10.1073\/pnas.1209182109","volume":"109","author":"G Sitia","year":"2012","unstructured":"Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improes survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"197_CR38","doi-asserted-by":"crossref","unstructured":"Rachidi S, Metelli A, Riesenberg B, et al. Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol, 2017;2:1\u201327.","DOI":"10.1126\/sciimmunol.aai7911"},{"key":"197_CR39","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.1073\/pnas.95.19.11301","volume":"95","author":"J Ruschoff","year":"1998","unstructured":"Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA. 1998;95:11301\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"197_CR40","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1158\/0008-5472.CAN-07-2562","volume":"67","author":"MA McIlhatton","year":"2007","unstructured":"McIlhatton MA, Tyler J, Burkholder S, et al. Nitric oxide-donating aspirin deriaties suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 2007;67:10966\u201375.","journal-title":"Cancer Res"},{"key":"197_CR41","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1093\/carcin\/bgm101","volume":"28","author":"MG Luciani","year":"2007","unstructured":"Luciani MG, Campregher C, Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through actiation of the checkpoint kinase ATM. Carcinogenesis. 2007;28:2207\u201317.","journal-title":"Carcinogenesis"},{"issue":"7","key":"197_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00431-014-2485-1","volume":"174","author":"Markus Schmugge","year":"2015","unstructured":"Schmugge M, Speer O, Kroiss S, et al. Monitoring aspirin therapy in children after interventional cardiac catheterization: laboratory measures, dose response, and clinical outcomes. Eur J Pediatr, 2015;174:933\u201341.","journal-title":"European Journal of Pediatrics"},{"key":"197_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamainternmed.2015.7927","volume":"176","author":"AJ Schoenfeld","year":"2016","unstructured":"Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172\u20134.","journal-title":"JAMA Intern Med"},{"key":"197_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u201346.","journal-title":"JAMA Intern Med"},{"key":"197_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","volume":"170","author":"MD Howell","year":"2010","unstructured":"Howell MD, Noack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784\u201390.","journal-title":"Arch Intern Med"},{"key":"197_CR46","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJM199905063401801","volume":"340","author":"ED Belay","year":"1999","unstructured":"Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye\u2019s syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340:1377\u201382.","journal-title":"N Engl J Med"},{"key":"197_CR47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0895-4356(00)00366-8","volume":"54","author":"E Autret-Leca","year":"2001","unstructured":"Autret-Leca E, Jonille-Bera AP, Llau ME, et al. Incidence of Reye\u2019s syndrome in France: a hospital-based surey. J Clin Epidemiol. 2001;54:857\u201362.","journal-title":"J Clin Epidemiol"},{"key":"197_CR48","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1001\/jama.1987.03390140075030","volume":"257","author":"ES Hurwitz","year":"1987","unstructured":"Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Serice study of Reye\u2019s syndrome and medications. Report of the main study. JAMA. 1987;257:1905\u201311.","journal-title":"JAMA"},{"key":"197_CR49","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1542\/peds.77.4.598","volume":"77","author":"MJ Barrett","year":"1986","unstructured":"Barrett MJ, Hurwitz ES, Schonberger LB, Rogers MF. Changing epidemiology of Reye syndrome in the United States. Pediatrics. 1986;77:598\u2013602.","journal-title":"Pediatrics"},{"key":"197_CR50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJM198510033131403","volume":"313","author":"ES Hurwitz","year":"1985","unstructured":"Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye\u2019s syndrome and medications. Report of the pilot phase. N Engl J Med. 1985;313:849\u201357.","journal-title":"N Engl J Med"},{"key":"197_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00000433-199312000-00008","volume":"14","author":"ET Smith Jr.","year":"1993","unstructured":"Smith ET Jr., Dais GJ. Medium-chain acylcoenzyme\u2014A dehydrogenase deficiency. Not just another Reye syndrome. Am J Forensic Med Pathol. 1993;14:313\u20138.","journal-title":"Am J Forensic Med Pathol"},{"key":"197_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2008.06.003","volume":"39","author":"JA Gosalakkal","year":"2008","unstructured":"Gosalakkal JA, Kamoji V. Reye syndrome and reye-like syndrome. Pediatr Neurol. 2008;39:198\u2013200.","journal-title":"Pediatr Neurol"},{"key":"197_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2165\/00148581-200709030-00008","volume":"9","author":"K Schror","year":"2007","unstructured":"Schror K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9:195\u2013204.","journal-title":"Paediatr Drugs"},{"key":"197_CR54","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0753-3322(00)88500-5","volume":"53","author":"E Gioannucci","year":"1999","unstructured":"Gioannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother. 1999;53:303\u20138.","journal-title":"Biomed Pharmacother"},{"key":"197_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","volume":"99","author":"D Eleftheriou","year":"2014","unstructured":"Eleftheriou D, Lein M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014;99:74\u201383.","journal-title":"Arch Dis Child"},{"key":"197_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Re Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Re Pharmacol Toxicol"},{"key":"197_CR57","first-page":"546","volume":"109","author":"I Cascorbi","year":"2012","unstructured":"Cascorbi I. Drug interactions\u2014principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109:546\u201355. quiz 556","journal-title":"Dtsch Arztebl Int"},{"key":"197_CR58","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1517\/14740338.2014.924924","volume":"13","author":"S Nalamachu","year":"2014","unstructured":"Nalamachu S, Pergolizzi JV, Raffa RB, Lakkireddy DR, Taylor R Jr. Drug\u2013drug interaction between NSAIDS and low-dose aspirin: a focus on cardioascular and GI toxicity. Expert Opin Drug Saf. 2014;13:903\u201317.","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0197-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-018-0197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:58:08Z","timestamp":1684616288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-018-0197-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,14]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1038\/s41431-018-0197-0","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,14]]},"assertion":[{"value":"8 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Burn has a longstanding relationship with Bayer Pharma who have supported the CaPP Cancer Prevention trials. He has received fees for delivering lectures on this topic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}